Host restriction factors for hepatitis C virus

World Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 1477-1486

  Zhou, Li Ya ^a   Zhang, Lei Liang ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

Entry; Hepatitis C virus; Host restriction factor; Interferon; Propagation; Replication

Indexed keywords

ANIMAL; DISEASE COURSE; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PATHOGENICITY; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; SIGNAL TRANSDUCTION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84977529764     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i4.1477     Document Type: Article

References (138)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]
2. Yamane D, McGivern DR, Masaki T, Lemon SM. Liver injury and disease pathogenesis in chronic hepatitis C. Curr Top Microbiol Immunol 2013; 369: 263-288 [PMID: 23463205 DOI: 10.1007/978 -3-642-27340-7_11]
3. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003; 7: 149-161 [PMID: 12691464]
4. Pereira AA, Jacobson IM. New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 2009; 6: 403-411 [PMID: 19575025 DOI: 10.1038/nrgastro.2009.92]
5. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]
6. Lai CK, Jeng KS, Machida K, Lai MM. Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J Virol 2008; 82: 8838-8848 [PMID: 18562541 DOI: 10.1128/JVI.00398-08]
7. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004; 5: 1109-1115 [PMID: 15496950 DOI: 10.1038/ni1125]
8. Goff SP. Genetic control of retrovirus susceptibility in mammalian cells. Annu Rev Genet 2004; 38: 61-85 [PMID: 15568972 DOI: 10.1146/annurev.genet.38.072902.094136]
9. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809, table of contents [PMID: 11585785 DOI: 10.1128/CMR.14.4.778-809.2001]
10. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503-524 [PMID: 9335428]
11. Silverman RH. Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J Interferon Res 1994; 14: 101-104 [PMID: 7523539]
12. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264 [PMID: 9759489 DOI: 10.1146/annurev. biochem.67.1.227]
13. Guo J, Peters KL, Sen GC. Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. Virology 2000; 267: 209-219 [PMID: 10662616 DOI: 10.1006/viro.1999.0135]
14. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113 [PMID: 10390360 DOI: 10.1126/science.285.5424.110]
15. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626 [PMID: 15947137 DOI: 10.1126/ science.1114016]
16. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 2012; 56: 2082-2093 [PMID: 22711689 DOI: 10.1002/ hep.25908]
17. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, McCartney EM, Jangra RK, Lemon SM, Beard MR. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 2011; 54: 1506-1517 [PMID: 22045669 DOI: 10.1002/hep.24542]
18. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485 [PMID: 21478870 DOI: 10.1038/nature09907]
19. Wilkins C, Woodward J, Lau DT, Barnes A, Joyce M, McFarlane N, McKeating JA, Tyrrell DL, Gale M. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013; 57: 461-469 [PMID: 22996292 DOI: 10.1002/hep.26066]
20. Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol 2014; 193: 783-796 [PMID: 24928988 DOI: 10.4049/jimmunol.1302563]
21. Bukong TN, Kodys K, Szabo G. Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection. Hepatology 2013; 58: 1569-1579 [PMID: 23703860 DOI: 10.1002/hep.26500]
22. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008; 65: 100-112 [PMID: 17914604 DOI: 10.1007/ s00018-007-7291-8]
23. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-41012 [PMID: 12867431 DOI: 10.1074/jbc.M302267200]
24. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68: 206-215 [PMID: 12210409 DOI: 10.1002/jmv.10196]
25. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771 [PMID: 10535997 DOI: 10.1073/pnas.96.22.12766]
26. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941 [PMID: 9794763 DOI: 10.1126/science.282.5390.938]
27. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718 DOI: 10.1093/emboj/cdf529]
28. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805 [PMID: 17325668 DOI: 10.1038/ nature05654]
29. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886 [PMID: 19182773 DOI: 10.1038/nature07684]
30. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341]
31. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581]
32. Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 2013; 110: 10777-10782 [PMID: 23754414 DOI: 10.1073/ pnas.1301764110]
33. Wu X, Lee EM, Hammack C, Robotham JM, Basu M, Lang J, Brinton MA, Tang H. Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. J Virol 2014; 88: 8433-8444 [PMID: 24829338 DOI: 10.1128/JVI.00081-14]
34. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139: 1243-1254 [PMID: 20064371 DOI: 10.1016/j.cell.2009.12.017]
35. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011; 7: e1001258 [PMID: 21253575 DOI: 10.1371/journal. ppat.1001258]
36. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol 2011; 85: 2126-2137 [PMID: 21177806 DOI: 10.1128/JVI.01531-10]
37. Erickson AK, Gale M. Regulation of interferon production and innate antiviral immunity through translational control of IRF-7. Cell Res 2008; 18: 433-435 [PMID: 18385680 DOI: 10.1038/ cr.2008.46]
38. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85: 12881-12889 [PMID: 21976647 DOI: 10.1128/JVI.05633-11]
39. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 2004; 198: 185-202 [PMID: 15199963 DOI: 10.1111/j.0105-2896.2004.0123. x]
40. Garlatti V, Martin L, Lacroix M, Gout E, Arlaud GJ, Thielens NM, Gaboriaud C. Structural insights into the recognition properties of human ficolins. J Innate Immun 2010; 2: 17-23 [PMID: 20375619 DOI: 10.1159/000233475]
41. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang X. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 2009; 6: 235-244 [PMID: 19728924 DOI: 10.1038/cmi.2009.32]
42. Haedicke J, de Los Santos K, Goff SP, Naghavi MH. The Ezrinradixin-moesin family member ezrin regulates stable microtubule formation and retroviral infection. J Virol 2008; 82: 4665-4670 [PMID: 18305045 DOI: 10.1128/JVI.02403-07]
43. Naghavi MH, Valente S, Hatziioannou T, de Los Santos K, Wen Y, Mott C, Gundersen GG, Goff SP. Moesin regulates stable microtubule formation and limits retroviral infection in cultured cells. EMBO J 2007; 26: 41-52 [PMID: 17170707 DOI: 10.1038/ sj.emboj.7601475]
44. Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 2001; 31: 166-175 [PMID: 11169450 DOI: 10.1002/1521-4141(20 0101)31: ]
45. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002; 12: 517-523 [PMID: 12446113 DOI: 10.1016/ S0962-8924(02)02383-8]
46. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-5492 [PMID: 12692249 DOI: 10.1128/JVI.77.9.5487-5492.2003]
47. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19 [PMID: 14752815 DOI: 10.1002/hep.20032]
48. Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol 2013; 87: 10612-10627 [PMID: 23885072 DOI: 10.1128/ JVI.01370-13]
49. Lyn RK, Singaravelu R, Kargman S, O’Hara S, Chan H, Oballa R, Huang Z, Jones DM, Ridsdale A, Russell RS, Partridge AW, Pezacki JP. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes. Sci Rep 2014; 4: 4549 [PMID: 25008545 DOI: 10.1038/srep04549]
50. Wacher C, Müller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 2007; 81: 860-871 [PMID: 17079283 DOI: 10.1128/JVI.01167-06]
51. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J 2008; 27: 3311-3321 [PMID: 19008854 DOI: 10.1038/ emboj.2008.241]
52. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-15628 [PMID: 9861020 DOI: 10.1073/pnas.95.26.15623]
53. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005; 42: 702-710 [PMID: 16108059 DOI: 10.1002/hep.20844]
54. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82: 1665-1678 [PMID: 18077728 DOI: 10.1128/JVI.02113-07]
55. Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci USA 2001; 98: 15125-15130 [PMID: 11752458 DOI: 10.1073/pnas.011593298]
56. Khaiboullina SF, Rizvanov AA, Holbrook MR, St Jeor S. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 2005; 342: 167-176 [PMID: 16150475 DOI: 10.1016/ j.virol.2005.07.035]
57. Fitzgerald KA. The interferon inducible gene: Viperin. J Interferon Cytokine Res 2011; 31: 131-135 [PMID: 21142818 DOI: 10.1089/jir.2010.0127]
58. Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. Proc Natl Acad Sci USA 2009; 106: 20452-20457 [PMID: 19920176 DOI: 10.1073/pnas.0911679106]
59. Wang S, Wu X, Pan T, Song W, Wang Y, Zhang F, Yuan Z. Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33. J Gen Virol 2012; 93: 83-92 [PMID: 21957124 DOI: 10.1099/vir.0.033860-0]
60. Xu L, Zhou L, Li P. CIDE proteins and lipid metabolism. Arterioscler Thromb Vasc Biol 2012; 32: 1094-1098 [PMID: 22517368 DOI: 10.1161/ATVBAHA.111.241489]
61. Magnusson B, Gummesson A, Glad CA, Goedecke JH, Jernås M, Lystig TC, Carlsson B, Fagerberg B, Carlsson LM, Svensson PA. Cell death-inducing DFF45-like effector C is reduced by caloric restriction and regulates adipocyte lipid metabolism. Metabolism 2008; 57: 1307-1313 [PMID: 18702959 DOI: 10.1016/j.metabol]
62. Erdtmann L, Franck N, Lerat H, Le Seyec J, Gilot D, Cannie I, Gripon P, Hibner U, Guguen-Guillouzo C. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. J Biol Chem 2003; 278: 18256-18264 [PMID: 12595532 DOI: 10.1074/ jbc.M209732200]
63. Singaravelu R, Delcorde J, Lyn RK, Steenbergen RH, Jones DM, Tyrrell DL, Russell RS, Pezacki JP. Investigating the antiviral role of cell death-inducing DFF45-like effector B in HCV replication. FEBS J 2014; 281: 3751-3765 [PMID: 24980280 DOI: 10.1111/ febs.12901]
64. Nagarajan VK, Jones CI, Newbury SF, Green PJ. XRN 5’→3’ exoribonucleases: structure, mechanisms and functions. Biochim Biophys Acta 2013; 1829: 590-603 [PMID: 23517755 DOI: 10.1016/j.bbagrm.2013.03.005]
65. West S, Gromak N, Proudfoot NJ. Human 5’ -> 3’ exonuclease Xrn2 promotes transcription termination at co-transcriptional cleavage sites. Nature 2004; 432: 522-525 [PMID: 15565158 DOI: 10.1038/nature03035]
66. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 5’ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci USA 2013; 110: 1881-1886 [PMID: 23248316 DOI: 10.1073/ pnas.1213515110]
67. Li Y, Yamane D, Lemon SM. Dissecting the roles of the 5’ exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus replication. J Virol 2015; 89: 4857-4865 [PMID: 25673723 DOI: 10.1128/JVI.03692-14]
68. Sedano CD, Sarnow P. Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2. Cell Host Microbe 2014; 16: 257-264 [PMID: 25121753 DOI: 10.1016/j.chom.2014.07.006]
69. Thibault PA, Huys A, Amador-Cañizares Y, Gailius JE, Pinel DE, Wilson JA. Regulation of Hepatitis C Virus Genome Replication by Xrn1 and MicroRNA-122 Binding to Individual Sites in the 5’ Untranslated Region. J Virol 2015; 89: 6294-6311 [PMID: 25855736 DOI: 10.1128/JVI.03631-14]
70. Moon SL, Blackinton JG, Anderson JR, Dozier MK, Dodd BJ, Keene JD, Wilusz CJ, Bradrick SS, Wilusz J. XRN1 stalling in the 5’ UTR of Hepatitis C virus and Bovine Viral Diarrhea virus is associated with dysregulated host mRNA stability. PLoS Pathog 2015; 11: e1004708 [PMID: 25747802 DOI: 10.1371/journal. ppat.1004708]
71. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 2008; 4: e1000231 [PMID: 19057663 DOI: 10.1371/ journal.ppat.1000231]
72. Köck J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008; 89: 1184-1191 [PMID: 18420796 DOI: 10.1099/vir.0.83507-0]
73. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300: 1112 [PMID: 12750511 DOI: 10.1126/science.1083338]
74. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, Landau NR, Weitzman MD. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 2009; 5: e1000439 [PMID: 19461882 DOI: 10.1371/ journal.ppat.1000439]
75. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2005; 2: 32 [PMID: 15943885 DOI: 10.1186/1742-4690-2-32]
76. Peng ZG, Zhao ZY, Li YP, Wang YP, Hao LH, Fan B, Li YH, Wang YM, Shan YQ, Han YX, Zhu YP, Li JR, You XF, Li ZR, Jiang JD. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology 2011; 53: 1080-1089 [PMID: 21480314 DOI: 10.1002/hep.24160]
77. Zhu YP, Peng ZG, Wu ZY, Li JR, Huang MH, Si SY, Jiang JD. Host APOBEC3G protein inhibits HCV replication through direct binding at NS3. PLoS One 2015; 10: e0121608 [PMID: 25811715 DOI: 10.1371/journal.pone.0121608]
78. Blagoveshchenskaya A, Mayinger P. SAC1 lipid phosphatase and growth control of the secretory pathway. Mol Biosyst 2009; 5: 36-42 [PMID: 19081929 DOI: 10.1039/b810979f]
79. Liu Y, Boukhelifa M, Tribble E, Morin-Kensicki E, Uetrecht A, Bear JE, Bankaitis VA. The Sac1 phosphoinositide phosphatase regulates Golgi membrane morphology and mitotic spindle organization in mammals. Mol Biol Cell 2008; 19: 3080-3096 [PMID: 18480408 DOI: 10.1091/mbc.E07-12-1290]
80. Liu Y, Boukhelifa M, Tribble E, Morin-Kensicki E, Uetrecht A, Bear JE, Bankaitis VA. The Sac1 phosphoinositide phosphatase regulates Golgi membrane morphology and mitotic spindle organization in mammals. Mol Biol Cell 2008; 19: 3080-3096 [PMID: 18480408 DOI: 10.1091/mbc.E07-12-1290]
81. Rohde HM, Cheong FY, Konrad G, Paiha K, Mayinger P, Boehmelt G. The human phosphatidylinositol phosphatase SAC1 interacts with the coatomer I complex. J Biol Chem 2003; 278: 52689-52699 [PMID: 14527956 DOI: 10.1074/jbc.M307983200]
82. Szul T, Sztul E. COPII and COPI traffic at the ER-Golgi interface. Physiology (Bethesda) 2011; 26: 348-364 [PMID: 22013193 DOI: 10.1152/physiol.00017.2011]
83. Zhang L, Hong Z, Lin W, Shao RX, Goto K, Hsu VW, Chung RT. ARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replication. PLoS One 2012; 7: e32135 [PMID: 22359663 DOI: 10.1371/journal.pone.0032135]
84. Li H, Yang X, Yang G, Hong Z, Zhou L, Yin P, Xiao Y, Chen L, Chung RT, Zhang L. Hepatitis C virus NS5A hijacks ARFGAP1 to maintain a phosphatidylinositol 4-phosphate-enriched microenvironment. J Virol 2014; 88: 5956-5966 [PMID: 24623438 DOI: 10.1128/JVI.03738-13]
85. Fan J, Liu J, Culty M, Papadopoulos V. Acyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule. Prog Lipid Res 2010; 49: 218-234 [PMID: 20043945 DOI: 10.1016/j.plipres.2009.12.003]
86. Dorobantu CM, Ford-Siltz LA, Sittig SP, Lanke KH, Belov GA, van Kuppeveld FJ, van der Schaar HM. GBF1- and ACBD3-independent recruitment of PI4KIIIβ to replication sites by rhinovirus 3A proteins. J Virol 2015; 89: 1913-1918 [PMID: 25410869 DOI: 10.1128/JVI.02830-14]
87. Dorobantu CM, van der Schaar HM, Ford LA, Strating JR, Ulferts R, Fang Y, Belov G, van Kuppeveld FJ. Recruitment of PI4KIIIβ to coxsackievirus B3 replication organelles is independent of ACBD3, GBF1, and Arf1. J Virol 2014; 88: 2725-2736 [PMID: 24352456 DOI: 10.1128/JVI.03650-13]
88. Greninger AL, Knudsen GM, Betegon M, Burlingame AL, Derisi JL. The 3A protein from multiple picornaviruses utilizes the golgi adaptor protein ACBD3 to recruit PI4KIIIβ. J Virol 2012; 86: 3605-3616 [PMID: 22258260 DOI: 10.1128/JVI.06778-11]
89. Sasaki J, Ishikawa K, Arita M, Taniguchi K. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J 2012; 31: 754-766 [PMID: 22124328 DOI: 10.1038/ emboj.2011.429]
90. Téoulé F, Brisac C, Pelletier I, Vidalain PO, Jégouic S, Mirabelli C, Bessaud M, Combelas N, Autret A, Tangy F, Delpeyroux F, Blondel B. The Golgi protein ACBD3, an interactor for poliovirus protein 3A, modulates poliovirus replication. J Virol 2013; 87: 11031-11046 [PMID: 23926333 DOI: 10.1128/JVI.00304-13]
91. Hong Z, Yang X, Yang G, Zhang L. Hepatitis C virus NS5A competes with PI4KB for binding to ACBD3 in a genotype-dependent manner. Antiviral Res 2014; 107: 50-55 [PMID: 24792752 DOI: 10.1016/j.antiviral.2014.04.012]
92. Cui Q, Jiang W, Wang Y, Lv C, Luo J, Zhang W, Lin F, Yin Y, Cai R, Wei P, Qian C. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology 2008; 47: 105-112 [PMID: 17935223 DOI: 10.1002/hep.21951]
93. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy K, Liang TJ. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132: 733-744 [PMID: 17258724 DOI: 10.1053/j.gastro.2006.11.045]
94. Kim KA, Lin W, Tai AW, Shao RX, Weinberg E, De Sa Borges CB, Bhan AK, Zheng H, Kamegaya Y, Chung RT. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 2009; 50: 705-711 [PMID: 19231005 DOI: 10.1016/j.jhep.2008.12.021]
95. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535 [PMID: 16299039 DOI: 10.1136/gut.2005.069674]
96. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Häussinger D. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488-490 [PMID: 12551851 DOI: 10.1096/fj.02-0664fje]
97. Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, Tsai WL, Hyppolite G, Chung RT. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol 2010; 84: 6060-6069 [PMID: 20375166 DOI: 10.1128/JVI.02484-09]
98. DeWitte-Orr SJ, Collins SE, Bauer CM, Bowdish DM, Mossman KL. An accessory to the ‘Trinity’: SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses. PLoS Pathog 2010; 6: e1000829 [PMID: 20360967 DOI: 10.1371/journal.ppat.1000829]
99. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990; 343: 531-535 [PMID: 2300204 DOI: 10.1038/343531a0]
100. Limmon GV, Arredouani M, McCann KL, Corn Minor RA, Kobzik L, Imani F. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. FASEB J 2008; 22: 159-167 [PMID: 17709607 DOI: 10.1096/fj.07-8348com]
101. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-296 [PMID: 9069289 DOI: 10.1038/386292a0]
102. Yew KH, Carsten B, Harrison C. Scavenger receptor A1 is required for sensing HCMV by endosomal TLR-3/-9 in monocytic THP-1 cells. Mol Immunol 2010; 47: 883-893 [PMID: 19914718 DOI: 10.1016/j.molimm.2009.10.009]
103. Dansako H, Yamane D, Welsch C, McGivern DR, Hu F, Kato N, Lemon SM. Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. PLoS Pathog 2013; 9: e1003345 [PMID: 23717201 DOI: 10.1371/journal.ppat.1003345]
104. Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 2014; 16: 569-579 [PMID: 25525790 DOI: 10.1016/ j.chom.2014.10.008]
105. Jones DM, McLauchlan J. Hepatitis C virus: assembly and release of virus particles. J Biol Chem 2010; 285: 22733-22739 [PMID: 20457608 DOI: 10.1074/jbc.R110.133017]
106. Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103 [PMID: 21146993 DOI: 10.1016/j.tim.2010.11.005]
107. Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007; 81: 13783-13793 [PMID: 17913825 DOI: 10.1128/JVI.01091-07]
108. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82: 2120-2129 [PMID: 18077707 DOI: 10.1128/JVI.02053-07]
109. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104: 5848-5853 [PMID: 17376867 DOI: 10.1073/pnas.0700760104]
110. Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wölk B, Kaderali L, Pietschmann T. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 2014; 88: 1433-1446 [PMID: 24173232 DOI: 10.1128/JVI.01815-13]
111. Lee JY, Acosta EG, Stoeck IK, Long G, Hiet MS, Mueller B, Fackler OT, Kallis S, Bartenschlager R. Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins. J Virol 2014; 88: 12422-12437 [PMID: 25122793 DOI: 10.1128/ JVI.01660-14]
112. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. J Virol 2008; 82: 9647-9656 [PMID: 18667498 DOI: 10.1128/ JVI.00914-08]
113. Gusarova V, Seo J, Sullivan ML, Watkins SC, Brodsky JL, Fisher EA. Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biol Chem 2007; 282: 19453-19462 [PMID: 17500069 DOI: 10.1074/jbc.M700475200]
114. Vieyres G, Dubuisson J, Pietschmann T. Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. Viruses 2014; 6: 1149-1187 [PMID: 24618856 DOI: 10.3390/v6031149]
115. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 2010; 84: 7243-7255 [PMID: 20444895 DOI: 10.1128/JVI.02636-09]
116. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009; 83: 2382-2385 [PMID: 19091864 DOI: 10.1128/JVI.01607-08]
117. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 2009; 106: 20889-20894 [PMID: 19864625 DOI: 10.1073/pnas.0907075106]
118. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010; 7: 51 [PMID: 20529266 DOI: 10.1186/1742-4690-7-51]
119. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P, Kellam P, Towers GJ, Neil SJ. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog 2010; 6: e1000843 [PMID: 20419159 DOI: 10.1371/ journal.ppat.1000843]
120. Sarojini S, Theofanis T, Reiss CS. Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol 2011; 30: 965-974 [PMID: 21919738 DOI: 10.1089/ dna.2011.1384]
121. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 2010; 84: 12646-12657 [PMID: 20943977 DOI: 10.1128/ JVI.01328-10]
122. Kong WS, Irie T, Yoshida A, Kawabata R, Kadoi T, Sakaguchi T. Inhibition of virus-like particle release of Sendai virus and Nipah virus, but not that of mumps virus, by tetherin/CD317/BST-2. Hiroshima J Med Sci 2012; 61: 59-67 [PMID: 23077864]
123. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430 [PMID: 18200009 DOI: 10.1038/nature06553]
124. Yang H, Wang J, Jia X, McNatt MW, Zang T, Pan B, Meng W, Wang HW, Bieniasz PD, Xiong Y. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci USA 2010; 107: 18428-18432 [PMID: 20940320 DOI: 10.1073/pnas.1011485107]
125. Amet T, Byrd D, Hu N, Sun Q, Li F, Zhao Y, Hu S, Grantham A, Yu Q. BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Curr Mol Med 2014; 14: 349-360 [PMID: 24236455 DOI: 10.2174/1566524013666131118111719]
126. Dafa-Berger A, Kuzmina A, Fassler M, Yitzhak-Asraf H, Shemer-Avni Y, Taube R. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology 2012; 428: 98-111 [PMID: 22520941 DOI: 10.1016/j.virol.2012.03.011]
127. Pan XB, Qu XW, Jiang D, Zhao XL, Han JC, Wei L. BST2/ Tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res 2013; 98: 54-60 [PMID: 23422647 DOI: 10.1016/j.antiviral.2013.01.009]
128. Fu Y, Rubin CS. Protein kinase D: coupling extracellular stimuli to the regulation of cell physiology. EMBO Rep 2011; 12: 785-796 [PMID: 21738220 DOI: 10.1038/embor.2011.139]
129. Bossard C, Bresson D, Polishchuk RS, Malhotra V. Dimeric PKD regulates membrane fission to form transport carriers at the TGN. J Cell Biol 2007; 179: 1123-1131 [PMID: 18086912 DOI: 10.1083/ jcb.200703166]
130. Nhek S, Ngo M, Yang X, Ng MM, Field SJ, Asara JM, Ridgway ND, Toker A. Regulation of oxysterol-binding protein Golgi localization through protein kinase D-mediated phosphorylation. Mol Biol Cell 2010; 21: 2327-2337 [PMID: 20444975 DOI: 10.1091/mbc.E10-02-0090]
131. Peretti D, Dahan N, Shimoni E, Hirschberg K, Lev S. Coordinated lipid transfer between the endoplasmic reticulum and the Golgi complex requires the VAP proteins and is essential for Golgi-mediated transport. Mol Biol Cell 2008; 19: 3871-3884 [PMID: 18614794 DOI: 10.1091/mbc.E08-05-0498]
132. Amako Y, Syed GH, Siddiqui A. Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein. J Biol Chem 2011; 286: 11265-11274 [PMID: 21285358 DOI: 10.1074/ jbc.M110.182097]
133. Wolffe AP, Tafuri S, Ranjan M, Familari M. The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol 1992; 4: 290-298 [PMID: 1622927]
134. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 1988; 85: 7322-7326 [PMID: 3174636]
135. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 2011; 76: 1402-1433 [PMID: 22339596 DOI: 10.1134/ S0006297911130049]
136. Kosnopfel C, Sinnberg T, Schittek B. Y-box binding protein 1-a prognostic marker and target in tumour therapy. Eur J Cell Biol 2014; 93: 61-70 [PMID: 24461929 DOI: 10.1016/j.ejcb.2013.11.007]
137. Chatel-Chaix L, Melançon P, Racine MÈ, Baril M, Lamarre D. Y-box-binding protein 1 interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production. J Virol 2011; 85: 11022-11037 [PMID: 21849455 DOI: 10.1128/JVI.00719-11]
138. Chatel-Chaix L, Germain MA, Motorina A, Bonneil É, Thibault P, Baril M, Lamarre D. A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production. J Virol 2013; 87: 11704-11720 [PMID: 23986595 DOI: 10.1128/JVI.01474-13]